Printer Friendly

ELAN HEART DRUG LAUNCHING IN EUROPE (Product Announcement)

 ELAN HEART DRUG LAUNCHING IN EUROPE
 ATHLONE, Ireland, Dec. 12 /PRNewswire/ -- Elan Corporation plc


(AMEX: ELN) today announced that it is the first company to receive a CPMP recommendation for approvals of a once-a-day Nifelan (nifedipine) which is being launched in the United Kingdom by Rhone Poulenc Rorer under the name Nifensar.
 The other countries where approval has now been received are Belgium, Luxembourg, The Netherlands, Denmark, Spain, Germany and Greece. In these countries Elan's market partner is Farmitilia Carlo Erba, which will market it under the brand name Unidipine.
 This product is already marketed in Ireland by Rhone Poulenc Rorer.
 In commenting on the announcement Donald E. Panoz, Elan's chairman and chief executive officer, stated that "this approval now makes Elan the only company to have once-daily versions of the three major calcium antagonists, Diltelan (diltiazem), Verelan (verapamil) and Nifelan (nifedipine).
 "Nifedipine is the world's largest selling calcium antagonist used for treating hypertension and angina with a worldwide addressable market of US$2 billion. The European market is approximately US$600 million. We are especially pleased that we have gained these approvals as it will put our marketing partners in a good position based on a recent report that a competitive product will not be available throughout Europe until mid-1992," said Panoz.
 Elan's formulation, which comes in a range of dosage strengths including the lowest starting dose, eliminates the variability seen with conventional forms of nifedipine and is the company's first product approved using the its INDAS tablet technology. In addition, this is the only once-daily formulation or nifedipine available in the U.K.
 Nifelan has been filed with regulatory authorities worldwide and is in the final stages of approval in the United States where it will be marketed by Miles.
 Elan Corporation plc is a leader in the specialized health care field of advanced reformulation and drug delivery, concentrating on improved drug absorption and utilization. Elan operates research and manufacturing facilities in Athlone, Republic of Ireland; Gainesville, Ga.; Enschede, Netherlands; Manila, Philippines; Brea, Calif., and Cambridge, Mass.
 -0- 12/12/91
 /CONTACT: Brian Crotty of Elan Corporation plc, 800-252-3526, or Thomas Redington of Redington Inc., 203-222-7399, or 212-926-1733, for Elan Corporation/
 (ELN) CO: Elan Corporation plc ST: IN: MTC SU: PDT SM-KW -- NY035 -- 1915 12/12/91 11:38 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Article Type:Product Announcement
Date:Dec 12, 1991
Words:382
Previous Article:IBM AND QUOTRON ANNOUNCE EXPANDED, ENHANCED RELATIONSHIP; IBM TO PROVIDE NEW PLATFORM, INSTALLATION, CUSTOMER SUPPORT SERVICE FOR QUOTRON SYSTEMS
Next Article:STATESWEST ANNOUNCES STRONG NOVEMBER OPERATING RESULTS
Topics:


Related Articles
ELAN'S SMOKING CESSATION PRODUCT -- FIRST OTC LAUNCH
/FIRST ADD -- NY081 -- ELAN'S NICOTINE PATCH APPROVED BY FDA/
ELAN NAMES GEANEY PRESIDENT AND CREATES OFFICE OF CHAIRMAN
ELAN EARNINGS UP 50 PERCENT THROUGH SECOND QUARTER
ELAN'S ONCE-DAILY FORMULATION OF NAPROXEN LICENSED TO SYNTEX IN THE U.K.
SYNTEX ACQUIRES EXCLUSIVE RIGHTS TO MARKET ELAN'S ONCE-DAILY NAPROXEN FORMULATION IN UNITED STATES
Zanaflex(TM) to be Launched in the UK
Elan Announces Record 2000 First Quarter Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters